Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15458MR)

This product GTTS-WQ15458MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15458MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5258MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ13269MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ349MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ10793MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ11841MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ4962MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ8061MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ6397MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW